You are here: Industry Insights > NSCLC

News List

EMA accepts marketing application for Imfinzi to treat NSCLC patients pharmaceufical-technology
October 11, 2017
MedImmune is the global biologics research and development division of AstraZeneca.
AstraZeneca's Tagrisso secures Breakthrough Therapy Designation in first-line NSCLC pharmafile
October 10, 2017
AstraZeneca has announced that its immunotherapy Tagrisso has been awarded Breakthrough Therapy Designation by the FDA for the first-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer
FDA grants breakthrough therapy designation to Tagrisso for NSCLC europeanpharmaceuticalreview
October 10, 2017
The FDA has granted Breakthrough Therapy Designation for Tagrisso for the 1st-line treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer…
Alcohol aversion drug disulfiram may combat chemotherapy resistance europeanpharmaceuticalreview
October 09, 2017
Alcohol aversion drug disulfiram may combat chemotherapy resistance in non-small cell lung cancer…
NICE recommends Bristol-Myers Squibb’s nivolumab for NSCLC patients on NHS pharmaceufical-technology
September 22, 2017
PD-L1 is involved in the body’s immune response to cancer and nivolumab demonstrates better effectiveness in patients who have more PD-L1 protein on their cancer cells.
Novartis receives EU approval for first-line use of Zykadia in ALK-positive advanced NSCLC cphi-online
July 03, 2017
In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival compared with SOC chemotherapy with maintenance.
FDA grants approval for Roche's ALK test as CDx for Zykadia biospectrumasia
June 02, 2017
The VENTANA ALK (D5F3) Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for ZYKADIA
Astellas announces decision to discontinue ASP8273 treatment pharmaasia
May 31, 2017
Astellas announces discontinuation of ASP8273 and close randomization for clinical study Protocol 8273-CL-0302.
Astellas Discontinues ASP8273 Treatment and Closes Randomization for Clinical Study Protocol 8273-CL americanpharmaceuticalreview
May 12, 2017
Astellas Pharma announced the discontinuation of ASP8273 treatment arm in late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus erlotinib/gefitinib for the first-line treatment metastatic...
FDA grants approval to Merck & Co.'s Keytruda as first-line combination therapy in NSCLC firstwordpharma
May 11, 2017
Merck & Co. announced Wednesday that the FDA awarded accelerated approval to Keytruda (pembrolizumab), in combination with Eli Lilly's Alimta (pemetrexed) and carboplatin.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page